Related Experiment Videos
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines
Peter R Carroll1, J Kellogg Parsons1, Gerald Andriole1
1From UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; City of Hope Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Dana-Farber/Brigham and Women's Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Moffitt Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
Abstract:
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals.